Drug Profile
Mericitabine
Alternative Names: R-7128; RG 7128; RG7320; RO 5024048Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pharmasset
- Developer Roche
- Class Antivirals; Pyrimidine nucleosides; Small molecules
- Mechanism of Action DNA-directed RNA polymerase inhibitors; Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 12 Feb 2016 Roche terminates a phase II trial in Hepatitis C in USA, Australia, Austria, Brazil, Canada, France, Germany, Italy, Mexico, New Zealand, Poland, Puerto Rico, Slovakia, Spain and United Kingdom due to decrease in percentage of participants (NCT01168856)
- 28 Jan 2015 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-experienced) in Australia, Canada, USA, Brazil, Mexico, Germany, France, Spain, Puerto Rico, Poland, New Zealand, Slovakia, United Kingdom, Austria, Italy (PO)
- 28 Jan 2015 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in Germany, France, Italy, Puerto Rico, Canada, USA, Australia, Poland, Austria, United Kingdom, Spain, New Zealand (PO)